RxDoctor Payments Data

Victor Lyapis, MD

Family Medicine · Colusa, CANPI 1760407936

Payments from drug & device makers

$36,656in general payments, 2019–2025

Across 1,886 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Kowa Pharmaceuticals America, Inc.$3K
  • Novo Nordisk$3K
  • AstraZeneca$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • GSK$2K
  • plus $18K from 52 others

What the payments were for

  • Food & beverage$36,494100%
  • Education$1610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)427$6,132
Kowa Pharmaceuticals America, Inc.196$3,093
Novo Nordisk137$2,706
AstraZeneca95$2,679
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC143$2,456
GSK72$1,795
Lilly USA, LLC61$1,538
Boehringer Ingelheim59$1,400
Bayer41$1,226
Takeda Pharmaceuticals U.S.A., Inc.68$1,160
Sumitomo Pharma America, Inc.50$1,110
Nestle Healthcare Nutrition Inc.52$1,052
Pfizer49$1,026
Amgen40$955
Esperion Therapeutics, Inc.54$934
Sunovion Pharmaceuticals Inc.46$876
Ironwood Pharmaceuticals, Inc43$689
Amarin Pharma, Inc.43$678
Johnson & Johnson23$398
Madrigal Pharmaceuticals14$395
Astellas Pharma US Inc18$392
Novartis15$389
Merck16$388
E.r. Squibb & Sons, L.L.C.12$371
Eisai Inc.10$323
Biohaven Pharmaceuticals, Inc.9$279
Aimmune Therapeutics, Inc.10$253
Almatica Pharma LLC12$234
Medtronic2$217
Biohaven Pharmaceutical Holding Company Ltd.6$148
Scilex Pharmaceuticals Inc.7$146
Idorsia Pharmaceuticals US Inc7$141
Phathom Pharmaceuticals, Inc.4$108
Redhill Biopharma Inc.5$96
Merz North America, Inc.3$75
Lundbeck LLC3$74
Otsuka America Pharmaceutical, Inc.3$73
Ardelyx, Inc.3$72
Arbor Pharmaceuticals, Inc.3$64
Sanofi-aventis U.S. LLC3$50
Currax Pharmaceuticals LLC3$48
Smith+Nephew2$45
Nalpropion Pharmaceuticals LLC2$35
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$33
Regeneron Healthcare Solutions, Inc.1$27
Azurity Pharmaceuticals, Inc.1$27
Vivus LLC1$27
Alfasigma USA, Inc.1$26
Xeris Pharmaceuticals, Inc.1$25
Viiv Healthcare Company1$23
Fidia Pharma USA Inc.1$23
Ultragenyx Pharmaceutical Inc.1$23
Dexcom, Inc.1$22
Exact Sciences1$21
IBSA Pharma Inc.1$17
Galderma Laboratories, L.p.1$16
Shield Therapeutics Inc1$15
Medicure Pharma Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,656 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$432,549
Medicare patients
804
Services billed
4,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase954$829,368
LinzessLinaclotide1,207$638,814
EliquisApixaban949$587,758
OzempicSemaglutide412$411,866
ZenpepLipase/Protease/Amylase293$328,769
JardianceEmpagliflozin487$301,929
JanumetSitagliptin Phos/Metformin Hcl414$246,253
FarxigaDapagliflozin Propanediol400$237,916
TradjentaLinagliptin405$221,493
Dexlansoprazole DrDexlansoprazole1,142$216,949
JubliaEfinaconazole211$192,690
MyrbetriqMirabegron376$186,589
BelsomraSuvorexant344$150,967
XareltoRivaroxaban223$129,680
ProliaDenosumab63$106,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Namzaric, Restasis$6,132$1,538,2542,277 claims
PfizerEliquis$1,026$587,758949 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$1,400$553,726952 claims
Novo NordiskOzempic, Rybelsus$2,706$475,361470 claims
MerckJanumet, Belsomra, Januvia$388$451,833853 claims
Aimmune Therapeutics, Inc.Zenpep$253$328,769293 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,679$273,605457 claims
Astellas Pharma US IncMyrbetriq$392$186,589376 claims
Johnson & JohnsonXarelto$398$129,680223 claims
Lilly USA, LLCTrulicity, Mounjaro$1,538$112,830111 claims
AmgenProlia$955$106,40363 claims
Sumitomo Pharma America, Inc.Gemtesa$1,110$103,391208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Colusa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →